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1. INTRODUCTION 
Recently, we have demonstrated the presence of 
muscarinic receptors in the rat adenohypophysis 
and described their biochemical characteristics [I]. 
Our results showed that in contrast to other brain 
regions [2] antagonist binding in this area is 
heterogeneous with the existence of at least two 
subclasses of sites [l]. 
Physiological data indicate that muscarinic 
receptors may be coupled to Ca*+-channels in cer- 
tain systems (3-5) and that calcium may then act 
as a second messenger. Extracellular calcium is re- 
quired for the release of several adenohypophysis 
hormones [6,7]. 
[3H]4NMPB (9.2 Ci/mmol) were prepared as in 
[2,8]. The purity of the compounds was > 97%. 
Methoxyverapamif (known also as ‘D-600’) was a 
gift from Dr T. Bartfai. Adult female rats of the 
CD strain were supplied by Levinstein’s farm 
(Yokneam, Israel) and maintained in an air- 
conditioned room at 24 f 2°C for 14 h fluorescent 
illumination and 10 h darkness daily. After an ad- 
justment period of at least 4 weeks, daily vaginal 
smears were taken and only those females having 
a regular 4-day estrous cycle were used. Since in [l] 
we found differences in the biochemical 
characteristics of muscarinic receptors in the 
adenohypophysis at various stages of the estrous 
cycle, we chose a well-defined physiological stage 
Here, we examined whether Ca*+ affects the 
biochemical characteristics of muscarinic binding 
in the adenohypophysis, using the highly specific, 
tritiated muscarinic antagonist, N-methyld-pi- 
peridyl benzilate ([3H]4NMPB). We also examined 
whether the heterogeneity of the binding sites in 
this area originates from different components of 
the muscarinic receptor. For this purpose we used 
the specific photolabile muscarinic antagonist, 
N-methyl-4-piperidyl azidobenzilate (azido- 
[3H]4NMPB), which has been shown to provide ir- 
reversible labeling of a M, 86 000 polypeptide in rat 
cortex [8]. 
- the estrous day - to investigate the effect of 
calcium. 
2.2. Binding assay 
2. EXPERIMENTAL 
2.1. Materials 
[3H]4NMPB (65 Ci/mmol) and azido- 
* To whom correspondence should be addressed 
Direct binding of [3H]4NMPB to muscarinic re- 
ceptors in homogenates of rat adenohypophysis 
(25”C, pH 7.4) was measured in modified Krebs- 
Hensleit buffer containing 25 mM Tris-HCI, 
118 mM NaCI, 4.69 mM KCl, 1.9 mM CaC12, 
0.54 mM MgClz, 1 .O mM NaH2POd and 11.1 mM 
glucose as in [l]. When the effect of removal of 
Ca2+ from the buffer was investigated, it contained 
0.1 mM EGTA and no Ca*+ was added. Experi- 
ments with methoxyverapamil (4 x IO-’ M) were 
carried out in buffer containing 1.9 mM Ca*+, as 
used in the control assay. 
2.3. Photolabeling 
P2 fraction was prepared as in [8] and incubated 
in modified Krebs-Hensleit solution (pH 7.4) [I] 
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containing 5 nM azido-[3H]4NMPB at room tem- 1.9 mM Ca’+, and yielded curvilinear Scatchard 
perature in the dark for 10 min. The reaction mix- plots indicating heterogeneity of binding with the 
ture was then photolyzed with a long-wave ultra- existence of at least two subclasses of sites. It 
violet spot light lamp (Thomas Scientific Ap- should be noted that the existence of site-site in- 
paratus, model B-lOOA) at a distance of 7.5 cm teractions among the muscarinic sites could not be 
with continuous stirring for 4 min. excluded ([l] and fig. 1A). 
2.4. Gel electrophoresis 
Polyacrylamide slab gel electrophoresis (7.5% 
acrylamide in 0.1% NaDodSOd) was used to 
resolve membrane proteins. The gels were cut 
manually into 1 mm slices, each was incubated 
overnight at 37°C with 4.5 cc of 3% Protosol (New 
England Nuclear) in scintillation medium 
(Hydroluma). Radioactivity was then measured in 
a scintillation spectrometer. Recovery of radioac- 
tivity from the gels was 80-90%, counting efficien- 
cy was 35%. Clathrin (MI 180 000), RNA 
polymerase (Mr 155 000), phosphorylase b (MI 
94 000), bovine serum albumin (Mr 67 000), 
ovalbumin (Mr 43 000), and carbonic anhydrase 
(MI 30 000) (Sigma) were used as Mr markers. 
As depicted in fig. lB, after the removal of 
Ca2+, a linear Scatchard plot is obtained, in- 
dicating the conversion of the heterogeneous 
population (fig. IA) into a homogeneous popula- 
tion of binding sites, with a dissociation constant 
value which is an intermediate between the 
dissociation constant values of the cy and P 
subclasses, obtained when Ca2+ is present in the 
reaction mixture (table 1). 
3. RESULTS AND DISCUSSION 
Since methoxyverapamil is known to block 
calcium uptake, we chose this compound as an ad- 
ditional mean to investigate the specificity of the 
Ca2+ effect on the binding. In agreement with the 
above findings, binding of [3H]4NMPB in the 
presence of this blocker (at 4 x lo-’ M) presents 
the same characteristics as those obtained after the 
removal of Ca2+ (fig. lC, table 1). These results 
indicate that calcium affects the heterogeneity of 
muscarinic antagonist binding sites. 
In previous work we have examined the binding 
of muscarinic antagonists to homogenates of rat 
adenohypophysis. Assays were carried out in 
modified Krebs-Hensleit solution containing 
The question arises whether the heterogeneity of 
binding sites in the adenohypophysis originates 
from different components of the muscarinic 
receptor, and how Ca2+ affects these components. 
H3-4NMPB BOUND ( fmole/mg prot 1 
Fig. 1. Scatchard plots of [3H]4NMPB binding to homogenates of adenohypophysis: in buffer containing 1.9 mM Ca2’ 
(A); in the absence of Ca2+ and in the presence of 0.1 mM EGTA in the reaction mixture (B); in the presence of 1.9 mM 
Ca2+ and 4 x IO-’ M methoxyverapami] in the reaction solution. 
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Table 1 
Binding characteristics of the muscarinic antagonist [3H]4NMPB, determined by direct binding 
in rat adenohypophysi? 
+ Ca2+b - ca2+c + Ca2+ + D-600d 
Dissociation constant 
(nM) 
K = 0.64 + 0.06 
& = K 11.2 * 0.25 2.45 f 0.04 & = 1.4 + 0.13 = 
Maxima1 binding capacity (fmol/mg protein) B&, = 65 f 5 100 10 + 
‘The dissociation constants and the binding capacities presented in this table are taken from analysis 
of the Scatchard plots shown in fig. 1 
bExpts were carried out in modified Krebs-Hensleit solution (see section 2) in the presence of 
1.9 mM Ca2+. (Y and p designate the higher and lower affinity antagonist binding sites, respectively 
‘Ca2+ was omitted from the reaction mixture, and 0.1 mM EGTA was added 
dThe binding reaction contained 1.9 mM Ca2+ and 4 x lo-’ M D-600 
Mwildl 200 100 50 30 200 100 50 30 , 
Slice Number 
Fig. 2. NaDodS04/polyacrylamide gel-radioactivity 
pattern of proteins from adenohypophysis membranes 
specifically labeled with 5 nM azido-[3H]4NMPB. After 
electrophoresis, gels were sliced into 1 mm pieces and the 
amount of radioactivity of each piece was determined 
(see section 2). 
To clarify this we used the photolabile antagonist 
azido-[3H]4NMPB. This agent provides an irrever- 
sible labeling of the receptor sites, thus enabling 
the detection of specifically labeled macro- 
molecules by gel electrophoresis [8]. When ex- 
periments were carried out in the presence of Ca’+ 
(fig. 2) the radioactivity profile of the gel revealed 
two major labeled macromolecules with app. M, of 
-86 000 and 160 000. Upon removal of Ca2+ from 
the incubation buffer, labeling from the it4,160000 
macromolecule disappeared, whereas the labeling 
of the Mr 86 000 polypeptide remained unchanged. 
Interestingly, the proportions of the populations in 
the binding experiments (table 1) are similar to the 
proportions of the specific peaks found in gel elec- 
trophoresis after covalent attachment of azido- 
[3H]4NMPB to membranes from adenohypophysis 
in the presence (fig. 2A), or absence (fig. 2B) of 
Ca’+. 
A possible explanation for the above phenomena 
is that in the adenohypophysis there are two in- 
dependent polypeptides, iK 86 000 and 160 000, 
which carry the muscarinic binding sites. The bin- 
ding to the A4, 160 000 polypeptide requires 
calcium. Another possibility is that calcium induc- 
ed polymerization of the M, 86 000 polypeptide to 
form the it& 160 000 macromolecule, concomitant- 
ly with an increase in the binding capacity. The se- 
cond explanation is more reasonable in view of [9]. 
We presented evidence that in the cortex and hip- 
pocampus a single specifically labeled protein 
macromolecule with an app. i& of 86 000 was 
detected by gel electrophoresis, while in the 
medulla-pons, cerebellum and cardiac atria, there 
was also a M, 160 000 band in addition to the Mr 
86 000 polypeptide. Under certain conditions, 
alkali or hydroxylamine treatment caused a 
dissociation of both larger macromolecules into a 
345 
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single Mr 40 000 polypeptide. These results strong- 
ly suggest that the muscarinic receptor exists in 
oligomeric forms and that both a dimer and 
tetramer of a basic M, 40 000 peptide may exist as 
interconvertible species. Based on this data, we 
have proposed a model to explain the biological ar- 
chitecture of the muscarinic receptors. This model, 
and the results described therein, are currently 
under investigation. 
In conclusion, our findings indicate that in vitro, 
calcium affects the muscarinic receptor subunits 
and supports a possible physiological role for 
calcium in the adenohypophysis. Experiments are 
being carried out in our laboratory to assess this 
hypothesis and to evaluate the physiological 
significance of such calcium effect. 
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